Loading…
Clinical-stage biotech developing LB-102, an oral antipsychotic drug candidate for schizophrenia.
Clinical-stage biotech developing LB-102, an oral antipsychotic drug candidate for schizophrenia.
Has no product revenue and pays for trials by selling shares, so each trial result affects how much capital it can raise. LB-102 is a modified form of amisulpride, an antipsychotic sold in Europe but never approved in the US, which gives it a safety record from abroad.
Moat: none (IP / patents). Pre-commercial; competes in a crowded antipsychotic market against established generics and branded drugs.
Headquarters: New York, New York, US · Founded: 2019 · Employees: 27
Size LB Pharmaceuticals (LBRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.36B, the 2061st largest of 3,117 United States companies the cockpit tracks. Shares closed at $42.01 on 6 Nov 2026.
Performance Over six months the shares gained 31.4%, against -15.7% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Short interest Short interest is 17.2% of the free float (15 Oct 2026).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$345,000 | -$321,000 | -$91,000 | -$4,000 | -$2,000 |
| EBITDA | -$94.8M | -$30.1M | -$64.7M | -$11.4M | -$2.81M |
| Net income | -$85.7M | -$25.2M | -$63.1M | -$6.28M | -$14.3M |
| Free cash flow | -$82.8M | -$35.3M | -$53.8M | -$12.1M | -$2.73M |
| Capital expenditure | $435,000 | $52,000 | $769,000 | $25,000 | $0 |
| Total debt | $5.22M | $3.57M | $3.70M | $0 | $24.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| LB Pharmaceuticals LBRX | $1.36B | +31% | n/a | n/a | n/a | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| AbbVie ABBV | $515B | +45% | +11% | 36% | 8.9× | -0.1% |
| Alkermes Public ALKS | $7.71B | +31% | +15% | 5% | 4.9× | 31.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LBRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.4% | -6.4% | highest of 21 |
| 6-month return | +31.4% | -15.7% | highest of 21 |
| Distance from 52-week high | -16.2% | -39.4% | 2nd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 1.4× | -7.4% | +12.7% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | 15.3× | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 2.4× | -15.4% | +3.9% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 2.0× | 8.5% | -5.3% |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | 15.5× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | 4.9× | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 0.5× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 8.9× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 5.2× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 5.0× | 4.0% | +27.9% |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | 417.6× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 44.5× | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | 226.6× | n/a | n/a |